|
Allele Symbol Allele Name Allele ID |
Pip4k2ctm1b(KOMP)Wtsi targeted mutation 1b, Wellcome Trust Sanger Institute MGI:5629320 |
||||||||||||
| Summary |
2 genotypes
|
|
|
Data Sources
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
IMPC - JAX
|
|
IMPC - JAX
|
 |
IMPC - JAX
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
Immune infiltrates in the liver from Pip4k2ctm1b(KOMP)Wtsi/Pip4k2ctm1b(KOMP)Wtsi mice
|
• in culture, CD4+ T cells isolated from spleen are hypersensitive to anti-CD3 plus anti-CD28 stimulated proliferation, as measured by 3H-thymidine incorporation
|
|
• increased CD4+ T cell number in spleen at 12-14 months of age
|
|
• increased CD8+ T cell number in spleen at 12-14 months of age
|
|
• decreased number of Foxp3+CD4+ Treg cells in spleen at 12-14 months of age
|
|
• increased plasma IgG3 levels at 12 months of age, consistent with increased T cell-derived IL-17 levels
|
|
• at 12-14 months of age, mice exhibit an increase in CD44+ active T cells and a decrease in CD62L+ naive T cells, suggesting that T cells are hyperactivated
|
|
• in culture, CD4+ T cells isolated from spleen are hypersensitive to anti-CD3 plus anti-CD28 stimulated proliferation, as measured by 3H-thymidine incorporation
|
|
• increased plasma MCP-1 levels at 12-14 months of age
|
|
• increased plasma interferon-gamma levels at 12-14 months of age
• plasma interferon-gamma levels are somewhat reduced at 24 h of rapamycin treatment and return to basal (pre-treatment) levels after 2 weeks of rapamycin treatment, similar to what is observed in wild-type controls
|
|
• increased plasma IL-10 levels at 12-14 months of age
|
|
• increased plasma IL-12 levels at 12-14 months of age
• plasma IL-12(p70) levels are not significantly altered in response to rapamycin treatment, similar to what is observed in wild-type controls
|
|
• increased plasma levels of IL-12(p40) levels at 12-14 months of age
• plasma levels of IL-12(p40) are reduced to wild-type levels at 24 h of rapamycin treatment and remain suppressed after 2 weeks of treatment; in contrast, rapamycin has no significant effect on plasma IL-12(p40) in wild-type controls
|
|
• increased plasma IL-2 levels at 12-14 months of age
• plasma IL-2 levels are not significantly altered in response to rapamycin treatment, similar to what is observed in wild-type controls
|
|
• increased plasma IL-4 levels at 12-14 months of age
|
|
• increased interferon-gamma secretion by CD4+ T cells isolated from spleen
|
|
• increased IL-17 secretion by CD4+ T cells isolated from spleen
|
|
• ratio of immune infiltrates per total area is significantly increased in liver tissue, indicating chronic inflammation without a specific trigger such as infection or injury
|
|
• mice develop enhanced immune responses resulting in autoimmunity
• mammalian target of rapamycin complex 1 (mTORC1) signaling is highly activated in several tissues
• hyperimmune phenotype can be partially ameliorated by treatment with rapamycin, the allosteric mTORC1 inhibitor
|
|
• immune cell infiltration in the intestine at 12-14 months of age
|
|
• immune cell infiltration in the salivary gland at 12-14 months of age
|
|
• immune cell infiltration in the liver at 12-14 months of age
• infiltrating immune cells in liver tissue are predominantly CD3+ T cells and B220+ B cells
• ratio of immune infiltrates per total area is significantly increased in liver tissue, indicating chronic inflammation
• area of immune infiltrates in liver is dramatically reduced after 2 weeks of rapamycin treatment
|
|
• immune cell infiltration in the kidney at 12-14 months of age
|
|
• immune cell infiltration in the lungs at 12-14 months of age
|
| N |
• mice do not exhibit enhanced insulin sensitivity and are not protected from obesity on a high-fat diet
|
|
• decreased blood urea nitrogen levels at 12 months of age
|
|
• increased plasma VEGF levels at 12-14 months of age
|
|
• increased plasma MCP-1 levels at 12-14 months of age
|
|
• increased plasma interferon-gamma levels at 12-14 months of age
• plasma interferon-gamma levels are somewhat reduced at 24 h of rapamycin treatment and return to basal (pre-treatment) levels after 2 weeks of rapamycin treatment, similar to what is observed in wild-type controls
|
|
• increased plasma IL-10 levels at 12-14 months of age
|
|
• increased plasma IL-12 levels at 12-14 months of age
• plasma IL-12(p70) levels are not significantly altered in response to rapamycin treatment, similar to what is observed in wild-type controls
|
|
• increased plasma levels of IL-12(p40) levels at 12-14 months of age
• plasma levels of IL-12(p40) are reduced to wild-type levels at 24 h of rapamycin treatment and remain suppressed after 2 weeks of treatment; in contrast, rapamycin has no significant effect on plasma IL-12(p40) in wild-type controls
|
|
• increased plasma IL-2 levels at 12-14 months of age
• plasma IL-2 levels are not significantly altered in response to rapamycin treatment, similar to what is observed in wild-type controls
|
|
• increased plasma IL-4 levels at 12-14 months of age
|
|
• increased plasma aspartate transaminase (AST) levels at 12 months of age
• however, plasma alanine transaminase (ALT) levels are normal
|
|
• increased CD4+ T cell number in spleen at 12-14 months of age
|
|
• increased CD8+ T cell number in spleen at 12-14 months of age
|
|
• decreased number of Foxp3+CD4+ Treg cells in spleen at 12-14 months of age
|
|
• increased plasma IgG3 levels at 12 months of age, consistent with increased T cell-derived IL-17 levels
|
|
• at 12-14 months of age, mice exhibit an increase in CD44+ active T cells and a decrease in CD62L+ naive T cells, suggesting that T cells are hyperactivated
|
|
• in culture, CD4+ T cells isolated from spleen are hypersensitive to anti-CD3 plus anti-CD28 stimulated proliferation, as measured by 3H-thymidine incorporation
|
|
• immune cell infiltration in the liver at 12-14 months of age
• infiltrating immune cells in liver tissue are predominantly CD3+ T cells and B220+ B cells
• ratio of immune infiltrates per total area is significantly increased in liver tissue, indicating chronic inflammation
• area of immune infiltrates in liver is dramatically reduced after 2 weeks of rapamycin treatment
|
|
• pale livers are occasionally seen in mice at >12 months of age
|
|
• immune cell infiltration in the intestine at 12-14 months of age
|
|
• immune cell infiltration in the salivary gland at 12-14 months of age
|
|
• immune cell infiltration in the kidney at 12-14 months of age
|
|
• immune cell infiltration in the lungs at 12-14 months of age
|
|
• immune cell infiltration in the salivary gland at 12-14 months of age
|
| N |
• mice develop normally and grow into adulthood with no obvious growth abnormalities
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 04/30/2024 MGI 6.23 |
|
|
|
||
Analysis Tools